FDA granted Orphan Drug Designation to Sanofi’s SAR446523, a monoclonal antibody targeting GPRC5D, for relapsed/refractory ...

SAR446523, an investigational antibody targeting GPRC5D, received FDA orphan drug status and is in phase 1 trials for ...

Sanofi's SAR446523 gains FDA orphan drug status, offering hope for relapsed multiple myeloma patients with its targeted ...

Sanofi’s SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma Designation granted for IgG1-based GPRC5D monoclonal antibody for the potential treatment ...

G protein-coupled receptor, class C, group 5, member D (GPRC5D) loss after chimeric antigen receptor (CAR) T-cell therapy in ...

DelveInsight's GPRC5D-directed Therapies Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices ...

Anti-GPRC5D chimeric antigen receptor (CAR) T-cell therapy can produce responses in patients with relapsed or refractory multiple myeloma (MM), according to a phase 2 trial published in the ...

Sanofi’s SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma Designation granted for IgG1-based GPRC5D monoclonal antibody for the potential treatment ...

GPRC5D-directed Therapies Epidemiology Segmentation The GPRC5D-directed therapies market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: ...

The GPRC5D-directed therapies market is witnessing robust growth, driven by the high unmet need in relapsed/refractory multiple myeloma. Innovative modalities like CAR-T cells, bispecific antibodies, ...

US FDA grants orphan drug designation to Sanofi’s SAR446523, a GPRC5D monoclonal antibody, earns to treat multiple myeloma: Paris Friday, August 1, 2025, 09:00 Hrs [IST] The US ...